vs
Side-by-side financial comparison of NexPoint Residential Trust, Inc. (NXRT) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $62.1M, roughly 1.1× NexPoint Residential Trust, Inc.). On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs -2.7%).
NexPoint Residential Trust, Inc. is a publicly traded real estate investment trust focused on acquiring, renovating, and operating multifamily residential properties primarily across high-growth Sun Belt markets in the United States. Its portfolio consists mainly of affordable and mid-tier apartment communities, targeting steady rental income growth and long-term asset value appreciation for investors.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
NXRT vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $70.6M |
| Net Profit | — | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | 8.4% | -56.7% |
| Net Margin | — | -49.0% |
| Revenue YoY | -2.7% | 81958.1% |
| Net Profit YoY | — | 54.9% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | — | ||
| Q3 25 | $62.8M | $70.6M | ||
| Q2 25 | $63.1M | — | ||
| Q1 25 | $63.2M | — | ||
| Q4 24 | $63.8M | — | ||
| Q3 24 | $64.1M | — | ||
| Q2 24 | $64.2M | — | ||
| Q1 24 | $67.6M | — |
| Q4 25 | — | — | ||
| Q3 25 | $-7.8M | $-34.6M | ||
| Q2 25 | $-7.0M | — | ||
| Q1 25 | $-6.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-8.9M | — | ||
| Q2 24 | $10.6M | — | ||
| Q1 24 | $26.3M | — |
| Q4 25 | 8.4% | — | ||
| Q3 25 | 11.8% | -56.7% | ||
| Q2 25 | 12.5% | — | ||
| Q1 25 | 11.7% | — | ||
| Q4 24 | 18.0% | — | ||
| Q3 24 | 8.7% | — | ||
| Q2 24 | 39.7% | — | ||
| Q1 24 | 60.7% | — |
| Q4 25 | — | — | ||
| Q3 25 | -12.4% | -49.0% | ||
| Q2 25 | -11.1% | — | ||
| Q1 25 | -10.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -13.8% | — | ||
| Q2 24 | 16.5% | — | ||
| Q1 24 | 38.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | $-0.31 | — | ||
| Q2 25 | $-0.28 | — | ||
| Q1 25 | $-0.27 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.35 | — | ||
| Q2 24 | $0.40 | — | ||
| Q1 24 | $1.00 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.7M | $490.9M |
| Total DebtLower is stronger | $1.6B | — |
| Stockholders' EquityBook value | $295.5M | $503.0M |
| Total Assets | $1.9B | $577.1M |
| Debt / EquityLower = less leverage | 5.39× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.7M | — | ||
| Q3 25 | $10.8M | $490.9M | ||
| Q2 25 | $13.6M | — | ||
| Q1 25 | $23.7M | — | ||
| Q4 24 | $23.1M | — | ||
| Q3 24 | $17.4M | — | ||
| Q2 24 | $21.3M | — | ||
| Q1 24 | $37.2M | — |
| Q4 25 | $1.6B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $1.5B | — |
| Q4 25 | $295.5M | — | ||
| Q3 25 | $322.9M | $503.0M | ||
| Q2 25 | $347.9M | — | ||
| Q1 25 | $379.9M | — | ||
| Q4 24 | $410.4M | — | ||
| Q3 24 | $447.1M | — | ||
| Q2 24 | $491.1M | — | ||
| Q1 24 | $512.8M | — |
| Q4 25 | $1.9B | — | ||
| Q3 25 | $1.8B | $577.1M | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $1.9B | — | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $2.0B | — |
| Q4 25 | 5.39× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.92× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $83.6M | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $83.6M | — | ||
| Q3 25 | $29.3M | $-84.6M | ||
| Q2 25 | $19.9M | — | ||
| Q1 25 | $28.3M | — | ||
| Q4 24 | $73.6M | — | ||
| Q3 24 | $27.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $19.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-84.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -120.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.86× | — | ||
| Q1 24 | 0.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
